PE20170943A1 - Anticuerpos que se unen a ccr6 y sus usos - Google Patents
Anticuerpos que se unen a ccr6 y sus usosInfo
- Publication number
- PE20170943A1 PE20170943A1 PE2017000723A PE2017000723A PE20170943A1 PE 20170943 A1 PE20170943 A1 PE 20170943A1 PE 2017000723 A PE2017000723 A PE 2017000723A PE 2017000723 A PE2017000723 A PE 2017000723A PE 20170943 A1 PE20170943 A1 PE 20170943A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- ccr6
- antibodies
- join
- cdr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
Abstract
Se refiere a un anticuerpo o fragmento del mismo que se une a CCR6 (receptor de quimiocina 6), que comprende una CDR1 de cadena pesada que comprende la secuencia de aminoacidos de SEQ ID NO: 31 y/o una CDR2 que comprende la secuencia SEQ ID NO: 32, 190, 239, 240, 241, 242, 254 o 255 y/o una CDR3 de que comprende la secuencia SEQ ID NO: 33; y/o comprende una CDR1 de cadena ligera que comprende la SEQ ID NO: 34, 191, 244, 245, 246 o 256, y/o una CDR2 que comprende la SEQ ID NO: 35, 247, 248 o SEQ ID NO: 257 y/o una CDR3 que comprende la SEQ ID NO: 36, 192 o 193. Dicho anticuerpo o fragmento del mismo es util en el tratamiento de artritis reumatoide esclerosis multiple, entre otros
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14189374 | 2014-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20170943A1 true PE20170943A1 (es) | 2017-07-13 |
Family
ID=51743336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017000723A PE20170943A1 (es) | 2014-10-17 | 2015-10-19 | Anticuerpos que se unen a ccr6 y sus usos |
Country Status (18)
Country | Link |
---|---|
US (1) | US10640564B2 (es) |
EP (1) | EP3207060A1 (es) |
JP (1) | JP6792552B2 (es) |
KR (1) | KR20170082536A (es) |
CN (1) | CN107108742A (es) |
AU (1) | AU2015332338A1 (es) |
BR (1) | BR112017007877A2 (es) |
CA (1) | CA2964300A1 (es) |
CL (1) | CL2017000912A1 (es) |
CO (1) | CO2017004753A2 (es) |
EA (1) | EA201790816A1 (es) |
IL (1) | IL251676A0 (es) |
MA (1) | MA41480A (es) |
MX (1) | MX2017004970A (es) |
PE (1) | PE20170943A1 (es) |
PH (1) | PH12017500699A1 (es) |
SG (2) | SG11201703002PA (es) |
WO (1) | WO2016059253A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA41480A (fr) | 2014-10-17 | 2017-12-19 | Glenmark Pharmaceuticals Sa | Anticorps qui se lient au ccr6 et leurs utilisations |
WO2020210816A1 (en) * | 2019-04-12 | 2020-10-15 | Methodist Hospital Research Institute | Therapeutic particles that enable antigen presenting cells to attack cancer cells |
CN117018202A (zh) * | 2019-07-08 | 2023-11-10 | 上海交通大学医学院附属瑞金医院 | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 |
US20230340089A1 (en) * | 2020-05-14 | 2023-10-26 | City Of Hope | Smc1a antibodies and uses thereof |
JP7214696B2 (ja) * | 2020-10-01 | 2023-01-30 | 一般財団法人 化学物質評価研究機構 | 新規in vitro皮膚感作性試験法 |
EP4259204A1 (en) * | 2020-12-14 | 2023-10-18 | Monash University | Ccr6 antibodies |
WO2023125793A1 (en) * | 2021-12-29 | 2023-07-06 | Nanjing Immunophage Biotech Co., Ltd | Anti-ccr6 antibodies and uses thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US20040197329A1 (en) * | 2000-10-13 | 2004-10-07 | Yasunori Nakayama | Remedies or preventives for rheumatoid arthritis |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
BRPI1005984A2 (pt) | 2009-02-23 | 2016-10-04 | Glenmark Pharmaceuticals Sa | anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit |
SG10201509499RA (en) * | 2010-11-19 | 2015-12-30 | Eisai R&D Man Co Ltd | Neutralizing anti-ccl20 antibodies |
BR112013023918A2 (pt) * | 2011-03-25 | 2016-12-13 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural |
WO2013005649A1 (ja) * | 2011-07-01 | 2013-01-10 | 協和発酵キリン株式会社 | 抗ヒトccr6抗体 |
RU2014105172A (ru) * | 2011-07-13 | 2015-08-20 | Мерк Шарп И Доум Корп. | Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения |
US20150337037A1 (en) | 2012-06-05 | 2015-11-26 | Msm Protein Technologies | Human monoclonal antibodies against human chemokine receptor ccr6 |
MA41480A (fr) | 2014-10-17 | 2017-12-19 | Glenmark Pharmaceuticals Sa | Anticorps qui se lient au ccr6 et leurs utilisations |
-
2015
- 2015-10-18 MA MA041480A patent/MA41480A/fr unknown
- 2015-10-19 SG SG11201703002PA patent/SG11201703002PA/en unknown
- 2015-10-19 WO PCT/EP2015/074178 patent/WO2016059253A1/en active Application Filing
- 2015-10-19 SG SG10201912424UA patent/SG10201912424UA/en unknown
- 2015-10-19 JP JP2017520318A patent/JP6792552B2/ja not_active Expired - Fee Related
- 2015-10-19 US US15/519,413 patent/US10640564B2/en not_active Expired - Fee Related
- 2015-10-19 CN CN201580069220.2A patent/CN107108742A/zh active Pending
- 2015-10-19 PE PE2017000723A patent/PE20170943A1/es unknown
- 2015-10-19 BR BR112017007877A patent/BR112017007877A2/pt not_active Application Discontinuation
- 2015-10-19 EA EA201790816A patent/EA201790816A1/ru unknown
- 2015-10-19 MX MX2017004970A patent/MX2017004970A/es unknown
- 2015-10-19 CA CA2964300A patent/CA2964300A1/en not_active Abandoned
- 2015-10-19 EP EP15781677.8A patent/EP3207060A1/en not_active Withdrawn
- 2015-10-19 AU AU2015332338A patent/AU2015332338A1/en not_active Abandoned
- 2015-10-19 KR KR1020177013237A patent/KR20170082536A/ko unknown
-
2017
- 2017-04-09 IL IL251676A patent/IL251676A0/en unknown
- 2017-04-12 PH PH12017500699A patent/PH12017500699A1/en unknown
- 2017-04-12 CL CL2017000912A patent/CL2017000912A1/es unknown
- 2017-05-11 CO CONC2017/0004753A patent/CO2017004753A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MA41480A (fr) | 2017-12-19 |
JP6792552B2 (ja) | 2020-11-25 |
SG10201912424UA (en) | 2020-02-27 |
AU2015332338A1 (en) | 2017-06-01 |
IL251676A0 (en) | 2017-06-29 |
KR20170082536A (ko) | 2017-07-14 |
MX2017004970A (es) | 2017-06-30 |
PH12017500699A1 (en) | 2017-10-09 |
US20180086836A1 (en) | 2018-03-29 |
CO2017004753A2 (es) | 2017-09-29 |
JP2017536101A (ja) | 2017-12-07 |
CA2964300A1 (en) | 2016-04-21 |
CL2017000912A1 (es) | 2017-12-15 |
US10640564B2 (en) | 2020-05-05 |
EP3207060A1 (en) | 2017-08-23 |
SG11201703002PA (en) | 2017-05-30 |
BR112017007877A2 (pt) | 2018-01-23 |
EA201790816A1 (ru) | 2018-03-30 |
WO2016059253A1 (en) | 2016-04-21 |
CN107108742A (zh) | 2017-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20170943A1 (es) | Anticuerpos que se unen a ccr6 y sus usos | |
PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
PE20142243A1 (es) | Anticuerpos que se unen a ox40 y sus usos | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
PE20180499A1 (es) | Anticuerpos de union a tau | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
PE20181046A1 (es) | Anticuerpos anti-tigit y metodos de uso | |
PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
PE20150002A1 (es) | Anticuerpos anti-fcrn | |
PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
PE20191319A1 (es) | Anticuerpos novedosos contra el factor xi y sus usos | |
AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
PE20190737A1 (es) | Anticuerpos anti-cd27 | |
PE20170286A1 (es) | Diacuerpos heterodimericos biespecificos y sus usos | |
PE20151289A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
PE20161392A1 (es) | Combinacion de lenalidomida y constructo de polipeptido, y sus usos | |
PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
PE20170125A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
EA201791422A1 (ru) | Фармацевтические продукты и устойчивые жидкие композиции антител к il-17 |